Advanced pancreatic cancer is resistant to chemotherapeutic drugs, resulting in limited treatment efficacy and poor prognosis. Combined administration of the chemotherapeutic gemcitabine and erlotinib is considered a potential first-line treatment for advanced pancreatic cancer. However, their comparative benefits and potential risks remain unclear.

中文翻译：

---

厄洛替尼联合化疗治疗晚期胰腺癌临床疗效和安全性的Meta分析

晚期胰腺癌对化疗药物产生耐药性，导致治疗效果有限，预后较差。化疗药物吉西他滨和厄洛替尼的联合给药被认为是晚期胰腺癌的潜在一线治疗方法。然而，它们的相对收益和潜在风险仍不清楚。